ESMO 2018 | Olaparib considerably increases PFS in ovarian cancer
Domenica Lorusso, MD, PhD, of the IRCCS National Cancer Institute, Milan, Italy, gives an overview of the SOLO-1 trial (NCT01844986); evaluating maintenance monotherapy with olaparib following chemotherapy in newly-diagnosed patients with BRCA-mutated ovarian cancer. Dr Lorusso suggests that significant increases in PFS, when compared to the placebo, may indicate a curative potential or at least long-term benefit of the treatment in the first-line setting. She also calls for BRCA mutation screening, a response predictor for this agent, at the point of ovarian cancer diagnosis. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
Get great new content delivered to your inboxSign up